Literature DB >> 29453240

Arvinas, Pfizer Team Up on PROTACs.

.   

Abstract

Biotechnology startup Arvinas is developing proteolysis-targeting chimeras (PROTAC) that combat cancer by degrading disease-causing proteins. The company's first PROTACs will target prostate and breast cancers, and a recent deal with Pfizer will allow Arvinas to develop PROTACs for other cancer types. ©2018 American Association for Cancer Research.

Entities:  

Year:  2018        PMID： 29453240     DOI： 10.1158/2159-8290.CD-NB2018-015

Source DB:  PubMed          Journal:  Cancer Discov        ISSN： 2159-8274            Impact factor:   39.397


  4 in total

Review 1.  Breaking the Fourth Wall: Modulating Quaternary Associations for Protein Regulation and Drug Discovery.

Authors:  Marcus J C Long; Dziyana Hnedzko; Bo Kyoung Kim; Yimon Aye
Journal:  Chembiochem       Date:  2019-04-01       Impact factor: 3.164

Review 2.  Applying Antibodies Inside Cells: Principles and Recent Advances in Neurobiology, Virology and Oncology.

Authors:  Congcong Zhang; Rina M Ötjengerdes; Julian Roewe; Rebeca Mejias; Andrea L J Marschall
Journal:  BioDrugs       Date:  2020-08       Impact factor: 5.807

Review 3.  The PROTAC technology in drug development.

Authors:  Yutian Zou; Danhui Ma; Yinyin Wang
Journal:  Cell Biochem Funct       Date:  2019-01-02       Impact factor: 3.685

4.  RNA-PROTACs: Degraders of RNA-Binding Proteins.

Authors:  Alice Ghidini; Antoine Cléry; François Halloy; Frédéric H T Allain; Jonathan Hall
Journal:  Angew Chem Int Ed Engl       Date:  2020-12-10       Impact factor: 15.336
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.